Related Experiment Video

Updated: Jun 12, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer

Hongbin Ji1

  • 1Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. hbji@sibs.ac.cn

Cancer Science
|June 22, 2010
PubMed

Insights

Non-small-cell lung cancer patients develop resistance to epidermal growth factor receptor tyrosine kinase inhibitors through cancer-cell-autonomous and non-cancer-cell-autonomous mechanisms. Understanding these pathways is key to overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenic mutations in the epidermal growth factor receptor (EGFR) kinase domain predict response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung carcinoma (NSCLC).
  • Despite initial efficacy, acquired resistance to TKIs leads to disease relapse in NSCLC patients.
  • Identifying mechanisms of TKI resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To propose a comprehensive framework for understanding drug resistance in NSCLC.
  • To differentiate between cancer-cell-autonomous and non-cancer-cell-autonomous mechanisms of TKI resistance.
  • To explore the role of cancer-stroma interactions in the development of drug resistance.

Main Methods:

  • Review and synthesis of existing literature on EGFR TKI resistance.
  • Conceptual framework development based on cancer systems biology.
  • Discussion of molecular mechanisms at cellular and microenvironmental levels.

Main Results:

  • Drug resistance can emerge from intrinsic properties of cancer cells (autonomous) or interactions with the tumor microenvironment (non-autonomous).
  • Autonomous resistance mechanisms include EGFR signaling network robustness, epigenetic alterations, and genetic changes.
  • Non-autonomous resistance involves interactions between cancer cells, stromal cells, and the extracellular matrix.

Conclusions:

  • Acquired resistance to EGFR TKIs in NSCLC is a complex process involving both cancer cell-intrinsic and extrinsic factors.
  • The tumor stroma significantly contributes to drug resistance through intricate cell-cell and cell-matrix communications.
  • Targeting both cancer cells and their microenvironment may offer novel strategies to overcome TKI resistance in NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...